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Viral hepatitis screening guideline before biological drug 
use in rheumatic patients
Abstract
Biological drugs (tumor necrosis factor inhibitors, rituximab, tocilizumab, abatacept, and tofacitinib) are important treatment alternatives 
in rheumatology, particularly for resistant patients. However, they may cause hepatitis B virus (HBV) and hepatitis C virus (HCV) reacti-
vation; for instance, HBV reactivation may occur in a patient who is an inactive hepatitis B surface antigen (HBsAg) carrier or who has 
resolved HBV infection. Therefore, the screening of patients before biological treatment and the application of a prophylactic treatment, 
particularly with respect to latent HBV infections, are recommended when necessary. This guideline covers pre-treatment screening and 
follow-up recommendations, if required, with respect to viral hepatitides in rheumatology patients who are planned to be given biolog-
ical drugs. Although this guideline is prepared for biological disease-modifying antirheumatic drugs (DMARDs), it is recommended to 
be used also for target-oriented DMARDS and medium–high dose corticosteroids (>7.5 mg prednisolone/day equivalent). It should be 
considered that the reactivation risk is higher when more than one immunosuppressive drug is used.
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Introduction
Biological drugs are drugs that specifically target one of the immune or genetic mediators that play a role in 
the development process of a disease (1). These drugs are important treatment alternatives in rheumatol-
ogy, particularly for resistant patients (2). Biological drugs [tumor necrosis factor (TNF) inhibitors, rituximab, 
tocilizumab, abatacept, tofacitinib] effectively suppress disease activity. However, they can cause some 
side-effects, such as latent tuberculosis (TB) reactivation, hepatitis B virus (HBV) reactivation, and demy-
elinating diseases because they are target l-directed molecules (3). Therefore, the screening of patients 
with respect to some diseases before biological treatment and the application of prophylactic treatment, 
particularly with respect to latent TB or HBV infections, are recommended when necessary.
HBV is transmitted through parenteral, vertical, sexual, and horizontal routes. One-third of the world’s pop-
ulation is infected by HBV (4). Currently, it is estimated that 240 million people are HBV carriers worldwide. 
HBV infection becomes chronic (HBsAg positivity longer than 6 months) at varying rates, according to the 
age at which HBV infection occurs. The rate of becoming an HBV carrier following vertical contamination 
is 95%, while the rates of becoming HBV carriers after infections during adolescence or in adult age are 
much lower, being approximately 15–20% and 4–5%, respectively. Hepatitis C virus (HCV) is an RNA virus 
transmitted through parenteral, vertical, and sexual routes. It is currently estimated that more than 185 mil-
lion people in the world are infected with HCV (5, 6). HCV is removed from the body of 30–50% of patients 
within 6 months after infection, while infection becomes chronic in 50–70% of patients.
According to the results of the HBV and HCV prevalence study in Turkey, the HBV carrier rate was 3.9%, 
while exposure to HBV was 30.4%, and anti-HCV positivity was 0.9% (7). HBV and HCV incidences in 
patients with rheumatoid arthritis and ankylosing spondylitis were found to be similar to those in the 
prevalence study (8).
In rheumatic diseases, HBV and HCV reactivation may develop with disease alterations or biological drug 
use (9, 10). HBV reactivation may occur in a patient who is an inactive HBsAg carrier or who has a resolved 
HBV infection. This is defined by the seroconversion of negative HBV DNA, or increase >1 log10 IU/mL 
in HBV titer, and/or hepatitis B e antigen (HBeAg )reversion, and the occurrence of active necroinflam-
matory liver disease characterized by a five-times higher ALT value. If the serum ALT level increases 2–3 
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times more than baseline and the level of HCV 
RNA increases ≥1 log, HCV reactivation occurs. 
HBV and HCV reactivation may sometimes be 
in the form of fibrosing cholestatic hepatitis. 
Additionally, it was reported that reactivation 
develops after immunosuppressive use in pa-
tients previously exposed to HBV and who had 
developed immunity to it. “Covalently closed 
circular DNA” (cccDNA), functioning as a tem-
plate during the replication of HBV, is found in 
the nuclei of hepatocytes of each patient with 
HBV infection. As the immune control on cccD-
NA is removed, HBV replication starts again in 
increased levels. On the other hand, the reacti-
vation risk is high when occult HBV infection is 
present (11). Occult HBV infection is defined as 
the detection of HBV DNA in the serum at very 
low titers (<200 IU/mL) in lymphatic system 
cells and/or in liver tissue in HBsAg-negative 
patients.
This guideline comprises pre-treatment 
screening and follow-up recommendations, 
if necessary, with respect to viral hepatitides 
in rheumatology patients in whom it was 
planned to give biological drugs to in Turkey. 
Although this guideline is prepared for biolog-
ical disease-modifying antirheumatic drugs 
(DMARDs), it is recommended to be also used 
for target-oriented DMARDS and medium–
high dose corticosteroids (>7.5 mg predniso-
lone/day equivalent). It should be considered 
that the reactivation risk is higher when more 
than one immunosuppressive drug is used. 
Patients are divided into four groups as very 
high, high, medium, and low-risk groups with 
respect to the HBV reaction risk according to 
HBV serology and the immunosuppressive reg-
imen to be used.
1.  Very high-risk patients (reactivation 
risk>20%)
• Patients who are HBsAg (+) to hepatitis 
B core antigen (Anti-HBc) (+) and tak-
ing rituximab (RTX) and ofatumumab.
2.  High-risk patients (reactivation risk 11-20%)
• Patients who are HBsAg (−)/Anti-HBc 
(+) and taking rituximab and ofatu-
mumab.
• Patients who are HBsAg (+)/Anti-HBc (+) 
and have been taking anthracycline de-
rivatives (doxorubicin or epirubicin) and 
>10 mg of prednisolone for ≥4 weeks.
3.  Medium-risk patients (reactivation risk 
1–10%)
• Patients who are HBsAg (+)/Anti-HBc 
(+) or HBsAg (−)/Anti-HBc (+) and tak-
ing anti-TNF agents (etanercept, adali-
mumab, certolizumab, or infliximab), 
T cell co-stimulation inhibitor (abata-
cept), interleukin (IL)-12/IL-23 inhibi-
tor (ustekinumab), integrin inhibitors 
(natalizumab orvedolizumab), and 
tyrosine kinase inhibitors (imatinib or 
nilotinib).
• Patients who are HBsAg (+)/Anti-HBc 
(+) and have been using <10 mg of 
prednisolone for ≥4 weeks.
• Patients who are HBsAg (−)/Anti-HBc 
(+) and have been using anthracycline 
derivatives (doxorubicin or epirubicin) 
and >10 mg of prednisolone for ≥4 
weeks.
4.  Low-risk patients (reactivation risk<1%)
• Patients who are HBsAg (+) or HBsAg 
(−)/anti-HBc (+) and have been using 
azathioprine, 6-Mercaptopurine, meth-
otrexate, intra-articular steroid, and cor-
ticosteroid at any dose for ≤1 weeks.
• Patients who are HBsAg (−)/Anti-HBc 
(+) and have been using <10 mg of 
prednisolone for ≥4 weeks.
In the American Gastroenterology Association 
2015 guidelines, although routine oral antiviral 
prophylaxis is recommended for high- and me-
dium-risk patients, routine prophylaxis is not rec-
ommended for low-risk patients (12). HBV screen-
ing must be performed for all patients scheduled 
to receive biological treatment. Patients are divid-
ed into five groups according to the first screen-
ing tests about HBV (Table 1). HCV screening 
should not be conducted for all patients but only 
for those patients specified in Table 2.
Viral hepatitis screening recommendations before 
biological drug use in rheumatic diseases
The total number of recommendations is 10: 
the first eight are related to HBV screening and 
the last two are about HCV screening.
Recommendation 1
HBV screening must be conducted in all pa-
tients before biological treatment (TNF inhib-
itors, RTX, tociluzumab, abatacept, tofacitinib) 
(Figure1). If screening has not been conduct-
ed previously, the patient has to be screened 
during control visits.
Recommendation 2
The first dose of HBV vaccine should be admin-
istered before the treatment, if possible, and to 
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Table 1. Patient groups according to viral hepatitis screening
  HBsAg Anti-HBs Anti-HBc total
Group 1 HBV seronegatives − − −
Group 2 Immunized with vaccine  − + −
Group 3 With previous HBV infection − − +
Group 4 With chronic HBV infection + − +
Group 5 With healed HBV infection-Naturally immunized − + +
HBsAg: hepatitis B surface antigen; Anti-HBs: antibody to hepatitis B surface antigen; Anti-HBc: antibody to hepatitis B core 
antigen; HBV: hepatitis B virus
Table 2. Patients to be screened for HCV infection
Patients showing a risky behavior
• IV and intranasal substance users
Patients exposed to risk
• Hemodialysis patients
• Patients with tattoos
• Exposure of security and health staff to blood with HCV
• Patients born to a mother with hepatitis C positive
• Patients who underwent blood–blood product transfusion before 1994 and those who 
underwent surgery 
Other cases
• HIV positive cases
• Patients diagnosed with high aminotransferase levels or with liver disease
IV: intravenous; HCV: hepatitis C virus; HIV: human immunodeficiency virus
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patients with all hepatitis B indicators as nega-
tive (Group 1). Because the vaccine response is 
low in patients receiving immunosuppressive 
treatment (12), it is recommended that vac-
cination should be administered as a double 
dose (two adult doses of HBV vaccine togeth-
er) in the 0th, 1st, 2nd, and 6th months.
Recommendation 3
Patients in group 2 have been previously vac-
cinated [HBsAg−, antibody to hepatitis B sur-
face antigen (Anti-HBs+, Anti-HBc tot−). If the 
Anti-HBs titer is ≥100 IU/mL, no additional op-
eration is needed because it is protective. Bio-
logical treatment may be initiated. However, if 
Anti-HBs is <100 IU/mL, double-dose vaccina-
tion in one application is recommended, and 
biological treatment may be initiated. 
Recommendation 4
When screening tests show HBsAg+, an-
ti-HBs−, and anti-HBc total+ (Group 3), this 
may implicate the presence of ongoing chron-
ic HBV infection. At this stage, HBeAg, anti-HBe, 
HBV DNA, anti-Delta tot, and liver function 
tests should be ordered for the evaluation of 
liver disease. Besides, liver ultrasonography is 
also recommended. Antiviral prophylaxis is 
necessary for these patients. It is ideal to make 
a hepatological evaluation at this stage.
• Irrespective of the HBV DNA titer, pro-
phylaxis is initiated with oral antivirals 
(entecavir 0.5 mg and tenofovir 245 
mg, 1 daily tablet), the genetic barrier 
of which is high and potent. Prophylaxis 
should be preferably initiated two weeks 
before the administration of immuno-
suppressive drugs or simultaneously at 
the latest (13).
• The treatment period should be until 
HBsAg becomes negative for patients 
with chronic B hepatitis. Oral antivirals 
having a protective purpose should be 
continued 6–12 months after immu-
nosuppressive and/or biological treat-
ments are completed. In cases in which 
drugs for B lymphocytes, such as ritux-
imab and atumumab, are used, prophy-
laxis must be continued for 12 months 
after the completion of treatment.
Recommendation 5
When the screening test results show HBsAg−, 
anti-HBs−, but anti-HBc total+ (Group 4), this 
means that those patients have a history of 
previous HBV infection. In that case, HBV DNA 
should be evaluated to rule out occult HBV in-
fection.
• If HBV DNA is positive, antiviral treat-
ment should be initiated according to 
the 4th recommendation. If HBV DNA 
is negative, vaccination should be per-
formed according to the above recom-
mendations.
• HBV DNA should be evaluated in 1–6 
month intervals (three months on aver-
age) in the group if HBV DNA is negative.
• If RTX and ofatumumab are to be giv-
en to the patient, antiviral prophylaxis 
should be applied even if the patient is 
HBV DNA negative.
Recommendation 6 
When the screening test results show HBsAg−, 
anti-HBs+, and anti-HBc total+ (Group 5), this 
implicates the presence of resolved HBV infec-
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Figure 1. Algorithm for screening and prophylaxis of HBV in rheumatic diseases before biological drugs use
HBV: hepatitis B virus; DMARDs: disease-modifying antirheumatic drugs; TNF: tumor necrosis factor; HBsAg: hepatitis B surface antigen; Anti-HBs: antibody to hepatitis B surface 
antigen; Anti-HBc: antibody to hepatitis B core antigen; HBeAg: hepatitis B e antigen; Anti-HBe: antibody to hepatitis B e antigen
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tion and natural immunity against HBV. To be 
certain, an HBV DNA test is recommended for 
patients in this group.
• If HBV DNA is positive, antiviral prophy-
laxis should be given according to the 
above recommendations.
• If HBV DNA is negative and the anti-HBs 
titer is <100 IU/mL, double-dose booster 
vaccination is applied.
• Anti-HBs titer is not a decisive indicator 
for antiviral prophylaxis.
• The HBV DNA test should be repeated 
in 1–6 months intervals (three months 
on average) in the group if HBV DNA is 
negative. If HBV DNA becomes positive, 
antiviral prophylaxis is initiated.
• If RTX and ofatumumab are to be ad-
ministered to the patient, antiviral pro-
phylaxis should be applied even if the 
patient is HBV DNA negative.
Recommendation 7
Patients administered with oral antivirals are 
followed-up once in 3–6 months. If HBV DNA 
becomes positive despite antiviral prophylaxis 
with lamivudine, such patients should be eval-
uated with regard to lamivudine resistance and 
the antiviral treatment should be switched to 
tenofovir.
Recommendation 8 
An anti-HCV test must be performed in individ-
uals in the risk group for HCV infection (Table 2). 
However, anti-HCV screening must be conduct-
ed for all patients to take RTX.
Recommendation 9 
HCV RNA must be evaluated in individuals 
found to be anti-HCV positive.
• If HCV RNA is negative, the test should 
be repeated three months later.
• HCV genotype must be determined in 
patients whose anti-HCV and HCV RNA 
are found to be positive, and they must 
be evaluated with respect to the pres-
ence of liver disease.
• The treatments, including TNF inhibitors, 
in HCV RNA patients generally do not 
deteriorate the disease, and so, these 
treatments may be used during fol-
low-up. When the regimens, including 
RTX, are preferred, the patients must be 
closely followed-up with regard to HCV 
reactivation.
• ALT and AST tests must be repeated 
once a month and HCV RNA test must 
be repeated once every three months in 
HCV RNA positive patients initiated bio-
logical drugs. In case of HCV reactivation 
(≥3 times increase in ALT level and ≥1 
log increase in HCV RNA titer), discontin-
uation of the immunosuppressive treat-
ment must be considered (14, 15).
Recommendation 10
Currently, there is no prophylactic treatment 
to prevent HCV reactivation. However, since 
effective direct-acting anti-HCV drug combina-
tion regimes will be available in Turkey in the 
near future, HCV positive cases may be treated 
accordingly, unless there is a contraindication 
to those new agents. 
Peer-review: Externally peer-reviewed.
Author Contributions: Concept - Ö.K.,T.K.; Design - Ö.K., 
T.K., B.Ö., S.K., M.İ., G.K., S.K.; Supervision - M.İ., G.K., S.K.; 
Materials - Ö.K., T.K., Y.K.; Data Collection and/or Pro-
cessing - Ö.K., T.K., Y.K Analysis and/or Interpretation 
- Ö.K., T.K., B.Ö., S.K., M.İ., G.K., S.K.; Literature Review 
- Ö.K., T.K., B.Ö., S.K., M.İ., G.K., S.K.; Writer - Ö.K., T.K.; 
Critical Review - Ö.K., T.K., B.Ö., S.K., Y.K., M.İ., G.K., S.K.
Conflict of Interest: No conflict of interest was de-
clared by the authors.
Financial Disclosure: The authors declared that this 
study has received no financial support. 
References
1. Staren ED, Essner R, Economou JS. Overview of 
biological response modifiers. Semin Surg On-
col 1989; 5: 379-84. [CrossRef]
2. Kavanaugh AF. Anti-tumor necrosis factor-al-
pha monoclonal antibody therapy for rheuma-
toid arthritis. Rheum Dis Clin North Am 1998; 
24: 593-614. [CrossRef]
3. Ramiro S, Gaujoux-Viala C, Nam JL, Smolen 
JS, Buch M, Gossec L, et al. Safety of synthetic 
and biological DMARDs: a systematic litera-
ture review informing the 2013 update of the 
EULAR recommendations for management of 
rheumatoid arthritis. Ann Rheum Dis 2014; 73: 
529-35. [CrossRef]
4. Winthrop KL, Calabrese LH. Let the fog be lifted: 
screening for hepatitis B virus before biological ther-
apy. Ann Rheum Dis 2011; 70: 1701-3. [CrossRef]
5. Ott JJ, Stevens GA, Groeger J, Wiersma ST. 
Global epidemiology of hepatitis B virus infec-
tion: new estimates of age-specific HBsAg se-
roprevalence and endemicity. Vaccine 2012; 
30: 2212-9. [CrossRef]
6. Messina JP, Humphreys I, Flaxman A, Brown A, 
Cooke GS, Pybus OG, et al. Global distribution 
and prevalence of hepatitis C virus genotypes. 
Hepatology 2015; 61: 77-87. [CrossRef]
7. Tozun N, Ozdogan OC, Cakaloglu Y, Idilman R, 
Karasu Z, Akarca US, et al. A nationwide prev-
alence study and risk factors for hepatitis A, B, 
C and D infections in Turkey. The 61th Annual 
Meeting, The American Association For The 
Study Of Liver Diseases (AASLD), Boston, MA-
USA: 2010; 789. 
8. Yilmaz N, Karadag O, Kimyon G, Yazici A, Yilmaz 
S, Kalyoncu, et al. Prevalence of hepatitis B and 
C infections in rheumatoid arthritis and anky-
losing spondylitis: A multicenter countrywide 
study. Eur J Rheumatol 2014; 1: 51-4. [CrossRef]
9. Jansen TL, Mulder CJ. Rheumatology meets 
hepatology in 2012: a clinician’s guideline for 
TNF inhibitors in hepatitis B/C virus carriers. Ex-
pert Opin Biol Ther 2012; 12: 391-3. [CrossRef]
10. Reddy KR, Beavers KL, Hammond SP, Lim JK, 
Falck-Ytter YT, American Gastroenterological 
Association I. American Gastroenterological As-
sociation Institute guideline on the prevention 
and treatment of hepatitis B virus reactivation 
during immunosuppressive drug therapy. Gas-
troenterology 2015; 148: 215-9; quiz e16-7.
11. Raimondo G, Filomia R, Maimone S. Therapy 
of occult hepatitis B virus infection and pre-
vention of reactivation. Intervirology 2014; 57: 
189-95. [CrossRef]
12. Kim DK, Bridges CB, Harriman KH, Centers for 
Disease C, Prevention, Advisory Committee on 
Immunization P, et al. Advisory committee on 
immunization practices recommended immu-
nization schedule for adults aged 19 years or 
older--United States, 2015. MMWR Morb Mortal 
Wkly Rep 2015; 64: 91-2. [CrossRef]
13. Di Bisceglie AM, Lok AS, Martin P, Terrault N, 
Perrillo RP, Hoofnagle JH. Recent US Food and 
Drug Administration warnings on hepatitis B 
reactivation with immune-suppressing and 
anticancer drugs: just the tip of the iceberg? 
Hepatology 2015; 61: 703-11. [CrossRef]
14. Mahale P, Kontoyiannis DP, Chemaly RF, Jiang Y, 
Hwang JP, Davila M, et al. Acute exacerbation 
and reactivation of chronic hepatitis C virus in-
fection in cancer patients. J Hepatol 2012; 57: 
1177-85. [CrossRef]
15. Pompili M, Biolato M, Miele L, Grieco A. Tumor 
necrosis factor-alpha inhibitors and chronic 
hepatitis C: a comprehensive literature re-
view. World J Gastroenterol 2013; 19: 7867-73. 
[CrossRef]
28
Eur J Rheumatol 2016; 3: 25-8Karadag et al. Viral hepatitis screening in rheumatic patients
